Frank Karbe - Myovant Sciences President

MYOV -  USA Stock  

USD 20.88  0.06  0.29%

  President
Mr. Frank L. Karbe is a Principal Financial, Accounting Officer of the Company., and as the interim Chief Financial Officer of Myovant Sciences, Inc. since September 2016. From September 2014 to July 2016, Mr. Karbe served as President of The Color Run, a global mass participation events platform. From January 2004 to June 2014, Mr. Karbe was the Executive Vice President and Chief Financial Officer of Exelixis, Inc., a publiclytraded biotechnology company. Prior to joining Exelixis in 2004, Mr. Karbe worked as an investment banker for Goldman Sachs Co., where he served most recently as Vice President in the healthcare group focusing on corporate finance and mergers and acquisitions in the biotechnology industry. Prior to joining Goldman Sachs in 1997, Mr. Karbe held various positions in the finance department of The Royal DutchShell Group in Europe. Mr. Karbe currently serves on the board of directors of Arbutus Biopharma Corporationrationration and Kolltan Pharmaceuticals, Inc. Mr. Karbe received his DiplomKaufmann from the WHUOtto Beisheim Graduate School of Management, Koblenz, Germany.
Age: 52  President Since 2020      
44 20 7400 3351  http://myovant.com

Frank Karbe Latest Insider Activity

Tracking and analyzing the buying and selling activities of Frank Karbe against Myovant Sciences stock is an integral part of due diligence when investing in Myovant Sciences. Frank Karbe insider activity provides valuable insight into whether Myovant Sciences is net buyers or sellers over its current business cycle. Note, Myovant Sciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Myovant Sciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Myovant Sciences Management Efficiency

Myovant Sciences has return on total asset (ROA) of (35.36) % which means that it has lost $35.36 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 20.67 %, meaning that it created $20.67 on every $100 dollars invested by stockholders. Myovant Sciences management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. Return on Average Equity is likely to climb to 1.09 in 2021, whereas Return on Average Assets are likely to drop (0.63)  in 2021. Myovant Sciences Total Assets are fairly stable at the moment as compared to the past year. Myovant Sciences reported Total Assets of 725.03 Million in 2020. Current Assets is likely to climb to about 760.3 M in 2021, whereas Return on Average Assets are likely to drop (0.63)  in 2021.
The company currently holds 369.7 M in liabilities with Debt to Equity (D/E) ratio of 138.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Myovant Sciences has a current ratio of 2.46, suggesting that it is liquid enough and is able to pay its financial obligations when due.
The market value of Myovant Sciences is measured differently than its book value, which is the value of Myovant that is recorded on the company's balance sheet. Investors also form their own opinion of Myovant Sciences' value that differs from its market value or its book value, called intrinsic value, which is Myovant Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myovant Sciences' market value can be influenced by many factors that don't directly affect Myovant Sciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myovant Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Myovant Sciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myovant Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Similar Executives

Found 4 records

PRESIDENT Since

Robert JanssenDynavax Technologies
2018
Michael OstrachDynavax Technologies
2016
David JohnsonDynavax Technologies
2014
Ryan SpencerDynavax Technologies
2019
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for womens health and endocrine diseases. Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd. Myovant Sciences operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 407 people. Myovant Sciences (MYOV) is traded on New York Stock Exchange in USA. It is located in 11-12 St. James’s Square and employs 407 people. Myovant Sciences is listed under Pharmaceutical Products category by Fama And French industry classification.

Myovant Sciences Leadership Team

Elected by the shareholders, the Myovant Sciences' board of directors comprises two types of representatives: Myovant Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Myovant. The board's role is to monitor Myovant Sciences' management team and ensure that shareholders' interests are well served. Myovant Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Myovant Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Keith Manchester, Director
Frank Karbe, Principal Financial and Accounting Officer, President and Chief Financial Officer of Myovant Sciences, Inc.
Juan Ferreira, Chief Commercial Officer - Myovant Sciences, Inc
Marianne Romeo, Head, Global Transactions & Risk Management
Mark Altmeyer, Independent Director
Frank Torti, Director
Vivek Ramaswamy, Director
Jeffrey Nornhold, Senior Vice President Pharmaceutical Operations & Development
Kim Sablich, Chief Commercial Officer
Wayne DeVeydt, Independent Director
Matthew Lang, General Counsel, Corporate Secretary and Chief Legal and Administrative Officer and Corporate Secretary of Myovant Sciences, Inc.
Kathleen Sebelius, Lead Independent Director
Adele Gulfo, Director, Interim Chief Commercial Officer
Mark Guinan, Independent Director
Myrtle Potter, Chairman of the Board
David Marek, Principal Executive Officer, Director
Terrie Curran, Independent Director
Hiroshi Nomura, Director
Lynn Seely, Principal Executive Officer, Director

Myovant Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Myovant Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Myovant Sciences Investors Sentiment

The influence of Myovant Sciences' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Myovant. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Current Sentiment - MYOV

Myovant Sciences Investor Sentiment

Most of Macroaxis users are now bullish on Myovant Sciences. What is your trading attitude regarding investing in Myovant Sciences? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Myovant Sciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Note that the Myovant Sciences information on this page should be used as a complementary analysis to other Myovant Sciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Complementary Tools for Myovant Stock analysis

When running Myovant Sciences price analysis, check to measure Myovant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Myovant Sciences is operating at the current time. Most of Myovant Sciences' value examination focuses on studying past and present price action to predict the probability of Myovant Sciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Myovant Sciences' price. Additionally, you may evaluate how the addition of Myovant Sciences to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Equity Search
Search for activelly traded equities including funds and ETFs from over 30 global markets
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
The market value of Myovant Sciences is measured differently than its book value, which is the value of Myovant that is recorded on the company's balance sheet. Investors also form their own opinion of Myovant Sciences' value that differs from its market value or its book value, called intrinsic value, which is Myovant Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myovant Sciences' market value can be influenced by many factors that don't directly affect Myovant Sciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myovant Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Myovant Sciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myovant Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.